(Q35696457)

9 August 2017

1 reference

title

AT1-receptor antagonism in hypertension: what has been learned with irbesartan? (English)

1 reference

9 August 2017

Bernard Waeber

1

1 reference

9 August 2017

Michel Burnier

series ordinal

2

1 reference

9 August 2017

language of work or name

1 reference

1 May 2003

1 reference

Expert Review of Cardiovascular Therapy

9 August 2017

published in

1 reference

9 August 2017

volume

1

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

23-33

1 reference

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Pharmacokinetics of irbesartan are not altered in special populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Drug interactions with irbesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

A population-based European cohort study of persistence in newly diagnosed hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Regression of left ventricular hypertrophy in human hypertension with irbesartan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Aten

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Treatment with irbesartan or atenolol improves endothelial function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.23

21 January 2018

Identifiers

DOI

10.1586/14779072.1.1.23

1 reference

9 August 2017

1 reference